scholarly journals Serum magnesium and proton-pump inhibitors use: a cross-sectional study

Author(s):  
Gustavo Adolpho Moreira Faulhaber ◽  
Bruna Maria Ascoli ◽  
Adriano Lubini ◽  
Márcio Mossmann ◽  
Gabriela Rossi ◽  
...  
2013 ◽  
Vol 59 (3) ◽  
pp. 276-279 ◽  
Author(s):  
Gustavo Adolpho Moreira Faulhaber ◽  
Bruna Maria Ascoli ◽  
Adriano Lubini ◽  
Márcio Mossmann ◽  
Gabriela Rossi ◽  
...  

2013 ◽  
Vol 14 (4) ◽  
pp. 265-269 ◽  
Author(s):  
Philipe de Souto Barreto ◽  
Maryse Lapeyre-Mestre ◽  
Céline Mathieu ◽  
Christine Piau ◽  
Catherine Bouget ◽  
...  

2019 ◽  
pp. 001857871987387
Author(s):  
Zabiuddin Ahad M ◽  
Alekhya Lavu ◽  
Maria Ansari ◽  
Raviraj Acharya V ◽  
Rajesh Vilakkathala

Background: Proton pump inhibitors (PPIs) are the most potent antacids used in clinical practice with greater safety and efficacy. Limited data are available on the usage of PPIs in Indian health-care settings. Our aim was to understand the usage pattern and potential drug interactions with concurrently administered medications employing a single-day cross-sectional study design. Methods: A prospective observational cross-sectional study conducted on a single day, at two tertiary care teaching hospitals in South India. Inpatients of above 18 years of age were included. Case profiles were reviewed and data were collected in predesigned forms and analyzed. Drug interactions were identified using Micromedex and Medscape drug-interaction databases. Results: A total of 797 case profiles screened from both the centers; 714 were prescribed with PPIs. In intensive care units (ICUs), the use of PPIs was highest with 95% of cases getting these drugs. A PPI was seen in about 93% of patients, who had more than or equal to 4 drugs in their prescriptions. Pantoprazole was the mostly prescribed PPI in around 90% of the cases. Around 33% of the PPIs usage was through IV (intravenous) route, and 75% of that use was seen in wards. Around 134 drug interactions were identified, of which 10 were of major severity. Conclusions: Around 90% of inpatients were prescribed with PPIs. Pantoprazole is the most commonly prescribed PPI (90%). The IV administration was seen more in wards than ICUs, and 10 major drug interactions were observed in this single-day study. Careful monitoring is needed to avoid serious drug interactions involving PPIs, and training programs should sensitize the clinicians on the evidence-based use of PPIs.


2020 ◽  
Vol 14 (2) ◽  
pp. 55-58
Author(s):  
Abdul Malik ◽  
Syed Mohkumuddin ◽  
Humaira Rahim ◽  
Shamima Hanif

Background: Proton pump inhibitors (PPIs) are in routine widely prescribed to hemodialysis patients. Recent studies have reported the association of PPIs use with hypomagnesemia in patients with long term hemodialysis. This study aims to determine the frequency of hypomagnesemia in patients of hemodialysis taking proton pump inhibitors. Patients and methods: This cross-sectional study was conducted in the Department of Nephrology of Sandman Provincial Hospital Quetta from 01-6-2019 till 01-9-2019. A total of 120 patients (52 PPI users and 68 non-PPI users) who were on HD for more than 06 months were included. Data regarding age, gender, duration of hemodialysis and taking PPIs were collected. Determination of serum magnesium was made by taking 3 different samples at 2 weeks’ interval and the mean value of serum magnesium was calculated. Serum Mg2+ levels <2.0 mg/dL was taken as hypomagnesemia. A Chi-square test was applied to determine the association of PPI use with hypomagnesemia. Results: Demographic variables such as age and gender were not significantly different between the groups. There was female dominance in both groups (73% in PPI groups and 66.1% in the non-PPI group (p-value 0.65). The mean duration of dialysis was 45.3±13.8 months in PPI users versus 48.9±12.9 months in non-PPI users (p-value 0.14). There was a significantly higher frequency of hypomagnesemia in PPI users; 36 (69.3%) versus 27 (39.7%) in non-PPI users (p-value 0.001). Conclusion: The use of PPI is associated with a significant reduction in serum magnesium levels. So serum magnesium levels should be advised as routine monitoring in patients of hemodialysis taking PPIs.


2013 ◽  
Vol 105 (3) ◽  
pp. 131-137 ◽  
Author(s):  
Jaime Alberto Sánchez-Cuén ◽  
Ana Bertha Irineo-Cabrales ◽  
Gregorio Bernal-Magaña ◽  
Felipe de Jesús Peraza-Garay

2015 ◽  
Vol 60 (8) ◽  
pp. 2280-2286 ◽  
Author(s):  
Orlaith B. Kelly ◽  
Catherine Dillane ◽  
Stephen E. Patchett ◽  
Gavin C. Harewood ◽  
Frank E. Murray

Sign in / Sign up

Export Citation Format

Share Document